StreetInsider.com News Articles

Form 4 Immunovant, Inc. For: Feb 25 Filed by: Gloria Melanie

Fri, 27 Feb 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260227/26081703.html

Form 4 Immunovant, Inc. For: Feb 25 Filed by: Gloria Melanie

Fri, 27 Feb 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260227/26081703.html

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Tue, 17 Feb 2026 10:48:00 -0500

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Tue, 17 Feb 2026 10:48:00 -0500

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Tue, 17 Feb 2026 10:48:00 -0500

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Tue, 17 Feb 2026 10:48:00 -0500

Form 144 Immunovant, Inc. Filed by: Geffner Michael

Tue, 10 Feb 2026 17:17:00 -0500

si-local-file:///var/storage/secattach/20260210/25977062.html

Form 144 Immunovant, Inc. Filed by: Geffner Michael

Tue, 10 Feb 2026 17:17:00 -0500

si-local-file:///var/storage/secattach/20260210/25977062.html

Immunovant (IMVT) PT Raised to $35 at JPMorgan

Mon, 09 Feb 2026 07:50:46 -0500

JPMorgan analyst Brian Cheng raised the price target on Immunovant (NASDAQ: IMVT) to $35.00 (from $34.00) while maintaining a Overweight rating.

Immunovant (IMVT) PT Raised to $44 at Guggenheim

Mon, 09 Feb 2026 07:07:30 -0500

Guggenheim analyst Yatin Suneja raised the price target on Immunovant (NASDAQ: IMVT) to $44.00 (from $41.00) while maintaining a Buy rating.

Immunovant (IMVT) PT Raised to $23 at Truist Securities

Mon, 09 Feb 2026 06:58:43 -0500

Truist Securities analyst Danielle Brill raised the price target on Immunovant (NASDAQ: IMVT) to $23.00 (from $22.00) while maintaining a Hold rating.

Immunovant (IMVT) PT Lowered to $49 at Stifel

Fri, 06 Feb 2026 10:13:51 -0500

Stifel analyst Alex Thompson lowered the price target on Immunovant (NASDAQ: IMVT) to $49.00 (from $50.00) while maintaining a Buy rating.

Form 10-Q Immunovant, Inc. For: Dec 31

Fri, 06 Feb 2026 07:24:00 -0500

si-local-file:///var/storage/secattach/20260206/25957980.html

Form 10-Q Immunovant, Inc. For: Dec 31

Fri, 06 Feb 2026 07:24:00 -0500

si-local-file:///var/storage/secattach/20260206/25957980.html

Form 8-K Immunovant, Inc. For: Feb 06

Fri, 06 Feb 2026 07:17:00 -0500

si-local-file:///var/storage/secattach/20260206/25957961.html

Form 8-K Immunovant, Inc. For: Feb 06

Fri, 06 Feb 2026 07:17:00 -0500

si-local-file:///var/storage/secattach/20260206/25957961.html

Immunovant, Inc. (IMVT) Tops Q3 EPS by 11c

Fri, 06 Feb 2026 07:05:40 -0500

Immunovant, Inc. (NASDAQ: IMVT) reported Q3 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72).

For earnings history and earnings-related data on Immunovant, Inc. (IMVT) click here.

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Fri, 06 Feb 2026 07:00:00 -0500

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026
IMVT-1402 development is progressing with potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren’s disease (SjD) remaining on track
Underwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant’s cash runway to the potential launch of IMVT-1402 in

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Fri, 06 Feb 2026 07:00:00 -0500

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026
IMVT-1402 development is progressing with potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren’s disease (SjD) remaining on track
Underwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant’s cash runway to the potential launch of IMVT-1402 in

Immunovant (IMVT) 2200 contracts of April 30 calls trade, share price up 2%

Mon, 26 Jan 2026 15:29:53 -0500

Immunovant (NASDAQ: IMVT) 30-day option implied volatility is at 76; compared to its 52-week range of 51 to 160 with a focus on 2200 contracts of April 30 calls as share price up 2%.

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026